Seres Therapeutics Inc

NASDAQ:MCRB   11:05:53 AM EDT
7.04
-0.05 (-0.70%)
Products

Seres Announces Topline Results For SER-287 Phase 2B Study In Mild-To-Moderate Ulcerative Colitis

Published: 07/22/2021 11:09 GMT
Seres Therapeutics Inc (MCRB) - Seres Therapeutics Announces Topline Results for Ser-287 Phase 2b Study in Mild-to-moderate Ulcerative Colitis.
Seres Therapeutics Inc - Primary Endpoint of Clinical Remission Compared to Placebo Was Not Achieved.
Seres Therapeutics Inc - Both Dosing Regimens of Ser-287 Were Generally Well Tolerated-.
Seres Therapeutics Inc - Open Label and Maintenance Portions of Ser-287 Study Will Be Closed.